MHCII nanoparticles for autoimmune hepatic diseases

DISEASE CATEGORY: Hepatic

INDICATION: Cirrhosis; hepatitis; liver disease

A team led by Parvus Therapeutics Inc. founder

Read the full 149 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE